AVEED (testosterone undecanoate) by Verity Pharmaceuticals is androgens, including testosterone and dihydrotestosterone (dht) are responsible for the normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. First approved in 2014.
Drug data last refreshed 14h ago · AI intelligence enriched 1mo ago
AVEED is a testosterone undecanoate injectable administered intramuscularly to treat male hypogonadism, a condition of insufficient testosterone production. The drug works by replacing or supplementing testosterone to restore normal development and maintenance of male sex characteristics, including muscle mass, bone density, and sexual function. It addresses both primary hypogonadism (gonadal defects) and secondary hypogonadism (hypothalamic or pituitary insufficiency).
Product is approaching loss of exclusivity with declining market relevance and minimal linked career opportunities in current job postings.
androgens, including testosterone and dihydrotestosterone (DHT) are responsible for the normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. These effects include the growth and maturation of prostate, seminal vesicles, penis, and scrotum; the…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Effects of Testosterone Undecanoate vs Placebo on Intrahepatic Fat Content in Overweight/Obese Men With T2DM or Prediabetes and Hypogonadism
Trial of Testosterone Undecanoate for Optimizing Performance During Military Operations
Ambulatory Blood Pressure Monitoring (ABPM) Extension Study of Oral Testosterone Undecanoate in Hypogonadal Men
Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men
Study to Compare DITEST to Testosterone Undecanoate in Adult Men With Hypogonadism
Worked on AVEED at Verity Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moPatent cliff in less than a year — expect lifecycle management and generic defense hiring
AVEED offers limited near-term career growth opportunities due to imminent loss of exclusivity and minimal current job openings. Career roles would focus on defending market share, managing generic transition, and supporting existing prescriber relationships rather than expansion.